Do Discounted Vouchers for Medical Cannabis Reduce Opioid Use in Adults With Pain (NCT04495725) | Clinical Trial Compass
CompletedNot Applicable
Do Discounted Vouchers for Medical Cannabis Reduce Opioid Use in Adults With Pain
United States270 participantsStarted 2020-10-06
Plain-language summary
This study will examine how discounted vouchers for medical cannabis use affects opioid analgesic use in adults with chronic pain. Our study findings will have critically important implications to shape clinical care and medical cannabis policies.
Who can participate
Age range18 Years – 99 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. \>18 years old
✓. English or Spanish fluency
✓. active certification for medical cannabis
✓. intends to have a soft-gel capsule product dispensed at Vireo Health
✓. medical cannabis qualifying conditions or complications of (a) chronic pain, or (b) pain that degrades health and functional capability as an alternative to opioid use or substance use disorder or (c) severe or chronic pain
✓. joint or neuropathic pain
✓. current severe pain
✓. dispensed opioids analgesics within the last 60 days
Exclusion criteria
✕. inability to provide informed consent
✕. inability to complete study visits over 14 weeks
✕. terminal illness
✕. current or prior psychotic disorder
✕. current or prior buprenorphine or methadone treatment for opioid use disorder
✕. NYS medical marijuana prescriber does not approve changes to product and dosing recommendations listed on the participant's certification form
What they're measuring
1
Opioid analgesic use
Timeframe: Opioid analgesic use will be weekly cumulative dose of opioid analgesics over 14 weeks.